Arbutus Biopharma Corporation

Arbutus Biopharma Corporation a biopharmaceutical company develops novel therapeutics for chronic Hepatitis B virus (HBV) infection SARS-CoV-2 and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729 a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens including HBsAg expression. The company's research and development programs include AB-161 an oral HBV RNA destabilizer; AB-101 an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses including COVID-19. It has licensing agreements with Gritstone Oncology Inc; Alnylam Pharmaceuticals Inc.; Qilu Pharmaceuticals Co Ltd; Assembly Biosciences Inc.; Acuitas Therapeutics Inc.; and Antios Therapeutics Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster Pennsylvania.